The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Plasma Copeptin and the Risk of Diabetes Mellitus
Open accessAbstract
BACKGROUND: Animal studies suggest that the arginine vasopressin system may play a role in glucose metabolism, but data from humans are limited. METHODS AND RESULTS: We analyzed plasma copeptin (copeptin), a stable C-terminal fragment of the arginine vasopressin prohormone. Using baseline and longitudinal data from a Swedish population-based sample (n=4742; mean age, 58 years; 60% women) and multivariable logistic regression, we examined the association of increasing quartiles of copeptin (lowest quartile as reference) with prevalent diabetes mellitus at baseline, insulin resistance (top quartile of fasting plasma insulin among nondiabetic subjects), and incident diabetes mellitus on long-term follow-up. New-onset diabetes mellitus was ascertained through 3 national and regional registers. All models were adjusted for clinical and anthropometric risk factors, cystatin C, and C-reactive protein. In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes mellitus (P=0.04) and insulin resistance (P<0.001). During 12.6 years of follow-up, 174 subjects (4%) developed new-onset diabetes mellitus. The odds of developing diabetes mellitus increased across increasing quartiles of copeptin, even after additional adjustment for baseline fasting glucose and insulin (adjusted odds ratios, 1.0, 1.37, 1.79, and 2.09; P for trend=0.004). The association with incident diabetes mellitus remained significant in analyses restricted to subjects with fasting whole blood glucose <5.4 mmol/L at baseline (adjusted odds ratios, 1.0, 1.80, 1.92, and 3.48; P=0.001). CONCLUSIONS: Elevated copeptin predicts increased risk for diabetes mellitus independently of established clinical risk factors, including fasting glucose and insulin. These findings could have implications for risk assessment, novel antidiabetic treatments, and metabolic side effects from arginine vasopressin system modulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Own result · 8 Own interpretation · 7 No full text of the sources · 4 Own method · 2 Supported · 1 Supported so far · 1 Partly supported · 1 Not checked yet · 1 No basis given · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“pharmacological blockade of the V2R, a potent stimulus of increased AVP secretion,35 was associated with a 5% incidence in hyperglycemic events during 30 days of tolvaptan treatment in patients with hyponatremia compared to 1% in controls, although numbers were small (12/223 vs 2/220).8”
§ Plasma copeptin and the risk of diabetes mellitus > DISCUSSION
What the sources say
- Supportedcites [8] source
Table 3 in the adverse-events and safety section reports hyperglycemia in 12 of 223 tolvaptan recipients (5%) and 2 of 220 placebo recipients (1%). The Methods describe a 30-day trial in patients with hyponatremia. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [35] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“On the other hand, given the strict HbA1c criteria for new-onset diabetes in the MHR and the fact that the NDR and Diabetes 2000 registers require a physician diagnosis according to established diagnostic criteria,28, 29 those classified as new-onset diabetes cases in our study are unlikely to be misclassified.”
§ Plasma copeptin and the risk of diabetes mellitus > DISCUSSION
What the sources say
- Partly supportedcites [28] sourceExperimental — accuracy not yet measured
The Research Design and Methods section says NDR data are reported by trained physicians and nurses during clinical visits and gives this study’s definition of type 2 diabetes. It does not say that NDR registration requires a physician diagnosis according to established diagnostic criteria. The MHR criteria and the citing authors’ inference about misclassification are not claims this citation specifically supports. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [29] source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continuous copeptin concentration at baseline was significantly higher in subjects who subsequently developed new-onset diabetes compared with those who did not, regardless of whether subjects with IFG at baseline were included (Table 3).”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The odds of insulin resistance increased with increasing copeptin in both crude analysis and after adjustment for model 1 covariates and FBG (Table 2).”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The association with incident diabetes remained significant in analyses restricted to subjects with fasting whole blood glucose <5.4 mmol/L at baseline (adjusted odds ratios 1.0, 1.80, 1.92, and 3.48; P=0.001).”
§ Plasma copeptin and the risk of diabetes mellitus > Abstract > Methods and Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and from 0.832 to 0.841 (P=0.007) when copeptin was added to the clinical model of diabetes prediction.”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes (P=0.04) and insulin resistance (P<0.001).”
- Also stated in: § RESULTS · plain
“The odds of insulin resistance increased with increasing copeptin in both crude analysis and after adjustment for model 1 covariates and FBG (Table 2).”
§ Plasma copeptin and the risk of diabetes mellitus > Abstract > Methods and Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In subjects free of diabetes at baseline, the area under the ROC curve increased from 0.694 to 0.710 (P=0.08) when copeptin was added to the personal model”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonetheless, after accounting for FBG and all other available diabetes risk factors, individuals in the top quartile of copeptin had a two- to three-fold excess risk of developing diabetes compared with those in the lowest quartile of copeptin.”
§ Plasma copeptin and the risk of diabetes mellitus > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“With addition of copeptin, the C-statistic from Cox regression models increased in subjects without diabetes at baseline from 0.702 to 0.718 in the personal model and from 0.835 to 0.844 in the clinical model.”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 3
- It may state two separate claims as one. 15
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, recent findings also indicate a cross-sectional association between plasma vasopressin and insulin resistance.3”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
What the sources say
- Supportedcites [3] source
The Discussion (page unavailable) reports an association between plasma copeptin and measures of insulin resistance, including HOMA-IR. It identifies copeptin as a surrogate for plasma vasopressin release, so the citing sentence is a reasonable paraphrase of an indirect finding; vasopressin itself was not measured. (LLM, conf=0.88)
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“mice who lack the V1bR have the opposite phenotype of lower fasting plasma glucose and increased insulin sensitivity.21”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
What the sources say
- Supportedcites [21] source
The Results report significantly lower fasting plasma glucose in V1bR−/− mice than in wild-type controls. The Discussion concludes that V1b receptor deficiency produces hypersensitivity to insulin. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In subjects without IFG, there was a significant improvement in the area under the ROC curve when copeptin was added to classical diabetes risk factors, consistent with an improvement in discrimination.”
§ Plasma copeptin and the risk of diabetes mellitus > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the segment of the population free of diabetes, i.e. in subjects with a range of glucose values that should not affect copeptin through osmolality, copeptin was positively associated with FBG (Figure 1). Additionally, copeptin was positively associated with plasma concentration of insulin (Figure 1).”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IDI was significantly improved by adding copeptin to the personal model for diabetes prediction in both non-diabetic subjects (P=0.01) and in non-IFG subjects (P=0.02) but non-significant when added to the clinical model (P=0.35 in non-diabetic individuals, P=0.09 in non-IFG individuals).”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In subjects free of IFG at baseline, the area under the ROC curve increased from 0.663 to 0.713 (P=0.03) and from 0.783 to 0.805 (P=0.04) when copeptin was added to the personal model and clinical model for diabetes prediction, respectively.”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When analyses were restricted to subjects without IFG at baseline, the C-statistic increased from 0.671 to 0.721 in the personal model and from 0.790 to 0.811 in the clinical model.”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among non-diabetic subjects at baseline, the Pearson correlation between copeptin and potential confounders, i.e. BMI, insulin and glucose, was 0.091, 0.12 and 0.10, respectively (P<0.001 for all).”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, FBG was the strongest risk factor for new-onset diabetes. Each 1 mmol/L increase of FBG at baseline increased the risk of future diabetes with an OR of 11.4 (95% CI 7.4–17.5) in the fully-adjusted model.”
§ Plasma copeptin and the risk of diabetes mellitus > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increasing quartile of copeptin was associated with new-onset diabetes using this criterion both in subjects free of diabetes at baseline (OR=1.42 95% CI=1.04–1.94; P=0.029) and in subjects free of IFG at baseline (OR=1.67 95% CI=1.07–2.63; P=0.025) after full adjustment”
§ Plasma copeptin and the risk of diabetes mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Mice lacking the V1aR display impaired glucose tolerance, insulin resistance and elevated AVP levels20”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [20] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Copeptin is a cleavage product of the C-terminal part of the AVP precursor that is produced in equimolar amounts with AVP, a process similar to the generation of insulin and C-peptide. In contrast to AVP, copeptin is stable, has a long half-life, and is not bound to platelets.”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [22] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Plasma AVP measurements are unreliable because AVP is unstable in vivo and ex vivo, is rapidly cleared from plasma, and is largely bound to platelets.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings suggest a model in which impaired signalling through the V1aR leads to elevated levels of AVP which in turn stimulates the V1bR and contributes to insulin resistance and diabetes development.”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Plasma copeptin, a marker of vasopressin level, is elevated in myocardial infarction1 and predict prognosis in patients who developed heart failure after myocardial infarction.2”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In addition, AVP action has been linked to liver glycogenolysis (V1aR) and insulin and glucagon secretion (V1bR).14, 15”
§ Plasma copeptin and the risk of diabetes mellitus > INTRODUCTION
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, these differences were equally, or more, pronounced when the study population was restricted to subjects free from IFG at baseline, excluding the possibility that our findings regarding established diabetes risk factors and copeptin in relation to new-onset diabetes were solely driven by subjects who had IFG at the MDC-CC baseline exam.”
§ Plasma copeptin and the risk of diabetes mellitus > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Plasma AVP measurements are unreliable because AVP is unstable in vivo and ex vivo, is rapidly cleared from plasma, and is largely bound to platelets.
“There are major concerns regarding the reliability of AVP measurements in plasma, as AVP is an unstable molecule both in vivo and ex vivo, is rapidly cleared from plasma and is largely attached to platelets in the circulation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large population studies report that high copeptin levels might predict the development of T2D (11).”
From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [11]
In the citing paper
“Copeptin shows potential as a rule-out marker in combination with troponin in myocardial infarction, and increased copeptin levels in heart failure are associated with worsened outcome (11).”
From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [11]
In the citing paper
“High plasma copeptin predicted future diabetes mellitus independently of known risk factors [18].”
From Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats (2015) · cites this paper as [18]
In the citing paper
“Recent findings reveal an independent association between plasma copeptin, a surrogate for vasopressin, and risk of diabetes.”
From Low Water Intake and Risk for New-Onset Hyperglycemia (2011) · cites this paper as [1]
In the citing paper
“Our data support the novel idea that vasopressin, besides its role in urine concentration, is also an important actor in glucose homeostasis (1).”
From Low Water Intake and Risk for New-Onset Hyperglycemia (2011) · cites this paper as [1]
Citations
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Comment on the provisional report from the WHO consultation
(1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00059.x · Cited by 1,820
Pencina, M. J., & D’Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1802 · Cited by 1,442
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Berglund, G., Elmståhl, S., Janzon, L., & LARSSON, S. A. (1993) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1993.tb00647.x · Cited by 640
Self-citationManjer, J., Carlsson, S., Elmståhl, S., Gullberg, B., Janzon, L., Lindström, M., Mattisson, I., & Berglund, G. (2001) · European Journal of Cancer Prevention · doi:10.1097/00008469-200112000-00003 · Cited by 543
Self-citationLolait, S. J., O'Carroll, A.-M., McBride, O. W., Konig, M., Morel, A., & Brownstein, M. J. (1992) · Nature · doi:10.1038/357336a0 · Cited by 524
Arginine Vasopressin in Advanced Vasodilatory Shock
Dünser, M. W., Mayr, A. J., Ulmer, H., Knotzer, H., Sumann, G., Pajk, W., Friesenecker, B. E., & Hasibeder, W. R. (2003) · Circulation · doi:10.1161/01.cir.0000066692.71008.bb · Cited by 523
Cited by
Sorted by citations
An obligatory role for neurotensin in high-fat-diet-induced obesity
Li, J., Song, J., Zaytseva, Y. Y., Liu, Y., Rychahou, P. G., Jiang, K., Starr, M. E., Kim, J. T., Harris, J. W., Yiannikouris, F. B., et al. (2016) · Nature · doi:10.1038/nature17662 · Cited by 268
Self-citationWater Intake, Water Balance, and the Elusive Daily Water Requirement
Armstrong, L. E., & Johnson, E. C. (2018) · Nutrients · doi:10.3390/nu10121928 · Cited by 274
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Bankir, L., Bouby, N., & Ritz, E. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.22 · Cited by 214
Enhörning, S., Bankir, L., Bouby, N., Struck, J., Hedblad, B., Persson, M., Morgenthaler, N. G., Nilsson, P. M., & Melander, O. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.88 · Cited by 197
Self-citationPlasma Copeptin, A Unifying Factor behind the Metabolic Syndrome
Enhörning, S., Struck, J., Wirfält, E., Hedblad, B., Morgenthaler, N. G., & Melander, O. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2981 · Cited by 177
Self-citationLow Water Intake and Risk for New-Onset Hyperglycemia
Roussel, R., Fezeu, L., Bouby, N., Balkau, B., Lantieri, O., Alhenc-Gelas, F., Marre, M., Bankir, L., & for the D.E.S.I.R. Study Group (2011) · Diabetes Care · doi:10.2337/dc11-0652 · Cited by 165
“Knowing the rise of vasopressin in diabetes, its effect on glycemia, gluconeogenesis, and glucagon release, it is surprising that no attention had been given to vasopressin as a possible risk factor for hyperglycemia and diabetes until a recent report of an association between copeptin and the incidence of diabetes (1…”
BackgroundPediatric Thermoregulation: Considerations in the Face of Global Climate Change
Smith, C. J. (2019) · Nutrients · doi:10.3390/nu11092010 · Cited by 177
“Evidence does indicate low fluid intake is independently associated with developing hyperglycemia [145], type 2 diabetes mellitus [146], and renal dysfunction including chronic kidney disease (CKD) [144], with inconsistent evidence of cardiovascular disease risk.”
BackgroundMelander, O., Maisel, A. S., Almgren, P., Manjer, J., Belting, M., Hedblad, B., Engström, G., Kilger, U., Nilsson, P. M., Bergmann, A., et al. (2012) · JAMA · doi:10.1001/jama.2012.12998 · Cited by 151
Self-citationMagnusson, M., Jujić, A., Hedblad, B., Engström, G., Persson, M., Struck, J., Morgenthaler, N. G., Nilsson, P. M., Newton‐Cheh, C., Wang, T. J., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2425 · Cited by 149
“For example, in the population-based Malmö Diet and Cancer (MDC) study cardiovascular cohort (MDC-CC), as many as 75% of those with diabetic fasting blood glucose values were unaware that they had diabetes (19).”
MethodSelf-citationCopeptin and its potential role in diagnosis and prognosis of various diseases
Dobsa, L., & Edozien, K. C. (2013) · Biochemia Medica · doi:10.11613/bm.2013.021 · Cited by 149
“tients with heart failure who generally have a lower osmolality (16,31).”
BackgroundMethodInfluentialRed cell distribution width, haemoglobin A 1c and incidence of diabetes mellitus
Engström, G., Smith, J. G., Persson, M., Nilsson, P. M., Melander, O., & Hedblad, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12188 · Cited by 134
Self-citationRoussel, R., Fezeu, L., Marre, M., Velho, G., Fumeron, F., Jungers, P., Lantieri, O., Balkau, B., Bouby, N., Bankir, L., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2295 · Cited by 133
Vasopressin and Copeptin in health and disease
Christ‐Crain, M. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09509-9 · Cited by 133
“Most but not all studies investigating copeptin levels in patients with type 2 diabetes showed a positive association of copeptin with blood glucose [95].”
BackgroundCopeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology
Bolignano, D., Cabassi, A., Fiaccadori, E., Ghigo, E., Pasquali, R., Peracino, A. P., Peri, A., Plebani, M., Santoro, A., Settanni, F., et al. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0379 · Cited by 125
High intakes of protein and processed meat associate with increased incidence of type 2 diabetes
Ericson, U., Sonestedt, E., Gullberg, B., Hellstrand, S., Hindy, G., Wirfält, E., & Orho‐Melander, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512003017 · Cited by 119
“HbA1c Register (date information for all the 835 additional cases that were identified by this register and for six of the cases without date information in Diabetes 2000)((23)) and (3) the Swedish National Diabetes Register (date information for U.”
BackgroundSelf-citationProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea
Bankir, L., Roussel, R., & Bouby, N. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00614.2014 · Cited by 113
Tada, H., Shiffman, D., Smith, J. G., Sjögren, M., Lubitz, S. A., Ellinor, P. T., Louie, J. Z., Catanese, J. J., Engström, G., Devlin, J. J., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006072 · Cited by 110
Self-citationAydın, S., Kuloğlu, T., & Aydın, S. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.001 · Cited by 111
A Review of the Nonpressor and Nonantidiuretic Actions of the Hormone Vasopressin
Mavani, G. P., DeVita, M. V., & Michelis, M. F. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00019 · Cited by 116
“In the rat model, chronic infusion of desmopressin (DDAVP) caused an increase in proteinuria and AVP suppression caused a decrease in proteinuria and improvement in renal function (16).”
BackgroundCopeptin is an independent predictor of diabetic heart disease and death
Enhörning, S., Hedblad, B., Nilsson, P. M., Engström, G., & Melander, O. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.11.020 · Cited by 99
Self-citationHydration for health hypothesis: a narrative review of supporting evidence
Perrier, E. T., Armstrong, L. E., Bottin, J. H., Clark, W. F., Dolci, A., Guelinckx, I., Iroz, A., Kavouras, S. A., Lang, F. J. W., Lieberman, H. R., et al. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02296-z · Cited by 108
Self-citationCopeptin predicts coronary artery disease cardiovascular and total mortality
Tasevska, I., Enhörning, S., Persson, M., Nilsson, P. M., & Melander, O. (2015) · Heart · doi:10.1136/heartjnl-2015-308183 · Cited by 98
Self-citationHydration, dehydration, underhydration, optimal hydration: are we barking up the wrong tree?
Kavouras, S. A. (2019) · European Journal of Nutrition · doi:10.1007/s00394-018-01889-z · Cited by 92
New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism
Bankir, L., & Yang, B. (2012) · Kidney International · doi:10.1038/ki.2012.67 · Cited by 88
Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men
Wannamethee, S. G., Welsh, P. I., Papacosta, O., LENNON, L. T., Whincup, P. H., & Sattar, N. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2362 · Cited by 92
“The association between copeptin and risk of incident diabetes in the present study was weaker than that observed in the MDC study (14).”
BackgroundResultInfluentialCopeptin and cardiovascular disease: A review of a novel neurohormone
Yalta, K., Yalta, T. D., Sıvrı, N., & Yetkın, E. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.039 · Cited by 89
“Copeptin in cardiometabolic disease [77–80] - May serve as a promising marker of cardiometabolic disease including DM, MetS (beyond”
BackgroundMethodInfluentialRole of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes
Hindy, G., Sonestedt, E., Ericson, U., Jing, X., Zhou, Y., Hansson, O., Renström, E., Wirfält, E., & Orho‐Melander, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2634-x · Cited by 91
“To identify cases that were not diagnosed at the hospital, we used the local HbA1c register, which contains data from institutional and non-institutional care in Malmö since 1988 [19].”
MethodSelf-citationTentzeris, I., Járai, R., Farhan, S., Perkmann, T., Schwarz, M. A., Jakl, G., Wojta, J., & Huber, K. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr049 · Cited by 89
“Copeptin has been shown to be elevated in haemorrhagic and septic shock,(19) acute ischaemic stroke,(20) and intracerebral bleeding,(21) as well as in patients with diabetes mellitus.(22) Copeptin levels were significantly higher in patients with a history of diabetes mellitus and significantly increased with higher N…”
BackgroundMetabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors
Johnson, R. J., Stenvinkel, P., Jensen, T., Lanaspa, M. A., Roncal, C., Song, Z., Bankir, L., & Sánchez‐Lozada, L. G. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121314 · Cited by 90
Boertien, W. E., Riphagen, I. J., Drion, I., Alkhalaf, A., Bakker, S. J. L., Groenier, K. H., Struck, J., de Jong, P. E., Bilo, H. J. G., Kleefstra, N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2922-0 · Cited by 86
“From the literature it is known that copeptin is associated with incident microalbuminuria in a general population cohort [23, 24] and with incident diabetes in the general population [11, 12].”
BackgroundSelf-citationTaveau, C., Chollet, C., Waeckel, L., Desposito, D., Bichet, D. G., Arthus, M.-F., Magnan, C., Philippe, E., Paradis, V., Foufelle, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3496-9 · Cited by 86
Self-citationAbbasi, A., Corpeleijn, E., Meijer, E., Postmus, D., Gansevoort, R. T., Gans, R. O. B., Struck, J., Hillege, H. L., Stolk, R. P., Navis, G., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2545-x · Cited by 86
“One recent study found that high baseline levels of copeptin are associated with increased risk for development of type 2 diabetes [6].”
BackgroundMethodResultInfluentialSelf-citationDimethylglycine Deficiency and the Development of Diabetes
Magnusson, M., Wang, T. J., Clish, C. B., Engström, G., Nilsson, P. M., Gerszten, R. E., & Melander, O. (2015) · Diabetes · doi:10.2337/db14-1863 · Cited by 72
“Incident diabetes (occurring after the MDC and MPP baseline examinations) was retrieved through record linkage of the Swedish personal identification number with national and regional registers as follows: the Malmö HbA1c register that analyzed all HbA1c samples at the Department of Clinical Chemistry obtained in inst…”
MethodSelf-citationHorsch, A., Kang, J. S., Vial, Y., Ehlert, U., Borghini, A., Marques-Vidal, P. M., Jacobs, I., & Puder, J. J. (2016) · British Journal of Health Psychology · doi:10.1111/bjhp.12197 · Cited by 78
Stookey, J. D., Kavouras, S. A., Suh, H., & Lang, F. J. W. (2020) · Nutrients · doi:10.3390/nu12040905 · Cited by 79
“Vasopressin-mediated pathways are associated with increased chronic disease mortality [19,34,37].”
BackgroundPlasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community
Roussel, R., Boustany, R. E., Bouby, N., Potier, L., Fumeron, F., Mohammedi, K., Balkau, B., Tichet, J., Bankir, L., Marre, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1113 · Cited by 74
“Other investigations have shown circulating copeptin to be positively correlated with insulin resistance and/or with the metabolic syndrome in African-American (21), non-Hispanic White American (21), and North European cohorts (35, 38), and with the incidence or the prevalence of T2DM in North European cohorts (22, 24…”
BackgroundDistinguishing Low and High Water Consumers—A Paradigm of Disease Risk
Armstrong, L. E., Muñoz, C. X., & Armstrong, E. G. (2020) · Nutrients · doi:10.3390/nu12030858 · Cited by 73
Cadmium Exposure and Incidence of Diabetes Mellitus - Results from the Malmö Diet and Cancer Study
Borné, Y., Fagerberg, B., Persson, M., Sällsten, G., Forsgard, N., Hedblad, B., Barregård, L., & Engström, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112277 · Cited by 68
“…incident diabetes was identified in the Malmo¨ HbA1c register (MHR), the Swedish National Diabetes Register (NDR), the Swedish inpatient register, the Swedish outpatient register, the nationwide Swedish drug prescription register and the regional Diabetes 2000 register of the Ska˚ne region [28,29].”
Self-citationArginine vasopressin: Direct and indirect action on metabolism
Yoshimura, M., Conway-Campbell, B. L., & Ueta, Y. (2021) · Peptides · doi:10.1016/j.peptides.2021.170555 · Cited by 75
Dmitrieva, N. I., Gagarin, A., Liu, D., Wu, C. O., & Boehm, M. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104404 · Cited by 70
Enhörning, S., Tasevska, I., Roussel, R., Bouby, N., Persson, M., Burri, P., Bankir, L., & Melander, O. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1595-8 · Cited by 71
“Furthermore, we showed that subjects with high copeptin concentration have an increased risk of all components of the metabolic syndrome [11, 14, 15] as well as cardiovascular disease and premature mortality, both in diabetics and non-diabetics [16–18].”
BackgroundMethodResultInfluentialSelf-citationTasevska, I., Enhörning, S., Christensson, A. G., Persson, M., Nilsson, P. M., & Melander, O. (2016) · American Journal of Nephrology · doi:10.1159/000447522 · Cited by 65
Self-citationIncreased Levels of Copeptin Before Clinical Diagnosis of Preeclampsia
Yeung, E. H., Liu, A., Mills, J. L., Zhang, C., Männistö, T. I., Lu, Z., Tsai, M. Y., & Mendola, P. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03762 · Cited by 65
“Epidemiological evidence have observed associations between elevated copeptin levels and increased risk of incident type 2 diabetes mellitus.(16,34) Despite these findings, our study showed no association between copeptin and risk of GDM.”
BackgroundRydberg, M., Zimmerman, M., Gottsäter, A., Nilsson, P. M., Melander, O., & Dahlin, L. B. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001298 · Cited by 66
Self-citationEffect of increased water intake on plasma copeptin in healthy adults
Lemetais, G., Melander, O., Vecchio, M., Bottin, J. H., Enhörning, S., & Perrier, E. T. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1471-6 · Cited by 64
“In an analysis conducted on a subset of participants in the Malmö diet and cancer study, higher baseline plasma copeptin was associated with increased prevalence of type 2 diabetes mellitus [2].”
MethodSelf-citationEnhörning, S., Brunkwall, L., Tasevska, I., Ericson, U., Tholin, J. P., Persson, M., Lemetais, G., Vanhaecke, T., Dolci, A., Perrier, E. T., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02195 · Cited by 67
“Individuals aged 20 to 75 years and had high plasma copeptin concentrations [>6.1 pmol · L in women and >10.7 pmol · L in men, corresponding to the top quartile of copeptin in the Malmö Diet and Cancer–Cardiovascular Cohort (6)] were deemed eligible for the current study and contacted by letter and telephone (Fig.”
BackgroundResultInfluentialSelf-citationCarlsson, S., Andersson, T., Araghi, M., Galanti, R., Lager, A., Lundberg, M., Nilsson, P., Norberg, M., Pedersen, N. L., Trolle‐Lagerros, Y., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12592 · Cited by 68
Self-citationVasopressin and metabolic disorders: translation from experimental models to clinical use
Nakamura, K., Velho, G., & Bouby, N. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12649 · Cited by 62
Reduced water intake deteriorates glucose regulation in patients with type 2 diabetes
Johnson, E. C., Bardis, C. N., Jansen, L. T., Adams, J. D., Kirkland, T. W., & Kavouras, S. A. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.05.004 · Cited by 67
Velho, G., Boustany, R. E., Lefèvre, G., Mohammedi, K., Fumeron, F., Potier, L., Bankir, L., Bouby, N., Hadjadj, S., Marre, M., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1003 · Cited by 60
Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus
Enhörning, S., Sjögren, M., Hedblad, B., Nilsson, P. M., Struck, J., & Melander, O. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0781 · Cited by 58
Self-citationVasopressin, from Regulator to Disease Predictor for Diabetes and Cardiometabolic Risk
Melander, O. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000446201 · Cited by 51
Self-citationVasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor
Andrés-Hernando, A., Jensen, T., Kuwabara, M., Orlicky, D. J., Cicerchi, C., Li, N., Roncal-Jiménez, C. A., García, G., Ishimoto, T., MacLean, P. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140848 · Cited by 56
“Elevated copeptin can also increase the risk of obesity and diabetes (17, 21).”
Thirst and Drinking Paradigms: Evolution from Single Factor Effects to Brainwide Dynamic Networks
Armstrong, L. E., & Kavouras, S. A. (2019) · Nutrients · doi:10.3390/nu11122864 · Cited by 63
Velho, G., Ragot, S., Boustany, R. E., Saulnier, P., Fraty, M., Mohammedi, K., Fumeron, F., Potier, L., Marre, M., Hadjadj, S., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0753-5 · Cited by 54
Sonestedt, E., Lyssenko, V., Ericson, U., Gullberg, B., Wirfält, E., Groop, L., & Orho‐Melander, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2444 · Cited by 57
“Type 2 diabetes cases were identified by three registers: the Swedish National Diabetes Register (18), the regional Diabetes 2000 register of the Skåne region (19), and the local HbA1c register (20).”
BackgroundSelf-citationApproach to the Patient: “Utility of the Copeptin Assay”
Christ‐Crain, M., Refardt, J. C., & Winzeler, B. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac070 · Cited by 56
Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin
Hellenkamp, K., Schwung, J., Rossmann, H., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00857-2015 · Cited by 53
von Haehling, S., Papassotiriou, J., Morgenthaler, N. G., Hartmann, O., Doehner, W., Stellos, K., Wurster, T. H., Schuster, A., Nagel, E. C., Gawaz, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.105 · Cited by 53
“Other clinical entities associated with elevated levels of copeptin include pulmonary disorders and cardiovascular diseases as well as insulin resistance and metabolic syndrome [14,38–40].”
BackgroundSelf-citationLong-term health outcomes associated with hydration status
Dmitrieva, N. I., Boehm, M., Yancey, P. H., & Enhörning, S. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00817-1 · Cited by 64
Self-citationShifting Focus: From Hydration for Performance to Hydration for Health
Perrier, E. T. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000462996 · Cited by 53
Carroll, H. A., Davis, M. G., & Papadaki, A. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.06.015 · Cited by 56
“Although this anti-diuretic hormone is traditionally associated with blood pressure regulation, it has also been shown to affect glucose homeostasis and insulin resistance [24-26].”
BackgroundLauber, C., Gerl, M. J., Klose, C. D., Ottosson, F. A., Melander, O., & Simons, K. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001561 · Cited by 49
“0% in the US National Glyco hemoglobin 5 Standardization Program (NGSP), in the Malmö HbA1c register [45].”
BackgroundSelf-citationGLUT4 Storage Vesicles: Specialized Organelles for Regulated Trafficking.
Li, D. T., Habtemichael, E. N., Julca-Zevallos, O., Sales, C., Westergaard, X. O., DeVries, S. G., Ruiz, D. M., Sayal, B. S., & Bogan, J. S. (2019) · Europe PMC (PubMed Central) · Cited by 46
Pikkemaat, M., Melander, O., & Boström, K. B. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.006 · Cited by 45
Self-citationMolvin, J., Pareek, M., Jujić, A., Melander, O., Råstam, L., Lindblad, U., Daka, B., Leósdóttir, M., Nilsson, P. M., Olsen, M. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36512-y · Cited by 43
Self-citationErrors in Dual Energy X-Ray Absorptiometry Estimation of Body Composition Induced by Hypohydration
Rodríguez-Sánchez, N., & Galloway, S. D. R. (2014) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2014-0067 · Cited by 44
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2021) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 50
“different AVP receptor sub-types; V2R in the renal collecting ducts [282], V1aR located in the liver and vasculature [283,284], V1bR in the”
Patsouras, A., Farmaki, P., Garmpi, A., Damaskos, C., Garmpis, N., Mantas, D., & Diamantis, E. (2019) · In Vivo · doi:10.21873/invivo.11572 · Cited by 41
Copeptin: Pathophysiology and potential clinical impact
Łukaszyk, E., & Małyszko, J. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.07.002 · Cited by 46
Enhörning, S., & Melander, O. (2018) · Annals of Nutrition and Metabolism · doi:10.1159/000488304 · Cited by 38
Self-citationCopeptin in obese children and adolescents: relationships to body mass index, cortisol and gender
Rothermel, J., Kulle, A. E., Holterhus, P., Toschke, C., Lass, N., & Reinehr, T. (2016) · Clinical Endocrinology · doi:10.1111/cen.13235 · Cited by 44
Genetics of Type 2 Diabetes: It Matters From Which Parent We Inherit the Risk
Lyssenko, V., Groop, L., & Prasad, R. B. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.233 · Cited by 41
Self-citationSontrop, J. M., Huang, S.-H., Garg, A. X., MOIST, L. M., House, A. A., Gallo, K., & Clark, W. F. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008634 · Cited by 39
“50 Copeptin is also inversely related to eGFR, is positively associated with urine protein, and is a prognostic biomarker for future events of diabetes and heart disease.(6) 8–11 27 28 51 Does it follow that hydration is a unifying factor linking copeptin to kidney function and other diseases, as some suggest?(52) Pos…”
BackgroundCopeptin as a Predictive Marker of Incident Heart Failure
Schill, F., Timpka, S., Nilsson, P. M., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13439 · Cited by 38
“Previous studies have shown a clear predictive role of copeptin in diabetes and diabetic heart disease.(12,13) A substantial number of patients had prevalent diabetes at start”
BackgroundMethodResultSelf-citationEffect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections · doi:10.1530/ec-17-0327 · Cited by 38
Lang, F. J. W., Guelinckx, I., Lemetais, G., & Melander, O. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000479640 · Cited by 38
Self-citationAcute-phase proteins and incidence of diabetes: a population-based cohort study
Muhammad, I. F., Borné, Y., Hedblad, B., Nilsson, P. M., Persson, M., & Engström, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0903-8 · Cited by 41
“To summarize, incident diabetes was identified by using the Malmö HbA1c register (MHR), the Swedish National Diabetes Register (NDR), the Swedish inpatient register, the Swedish outpatient register, the nationwide Swedish drug prescription register, and the regional Diabetes 2000 register of the Skåne region [20, 21].”
BackgroundMethodSelf-citationMeijer, E., Boertien, W. E., Zietse, R., & Gansevoort, R. T. (2011) · Kidney & Blood Pressure Research · doi:10.1159/000326902 · Cited by 38
“Furthermore, this study showed that copeptin concentration was positively associated with the amount of urinary albumin excretion (fig. 2 a), even after adjustment for potential confounders. The association between albuminuria and copeptin was as strong as the association between albuminuria and known risk factors for…”
BackgroundAcute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1Areceptors
Taveau, C., Chollet, C., Bichet, D. G., Velho, G., Guillon, G., Corbani, M., Roussel, R., Bankir, L., Melander, O., & Bouby, N. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00269.2016 · Cited by 38
“It has been shown that plasma copeptin, a validated surrogate marker for AVP derived from the same preprohormone (30, 45), is associated with insulin resistance, metabolic syndrome, and obesity, and that high-plasma copeptin predicts future diabetes mellitus, independently of known risk factors (10, 13, 15, 43, 44, 46…”
BackgroundSelf-citationAcute effects of salt on blood pressure are mediated by serum osmolality
Kanbay, M., Aslan, G., Afşar, B., Dağel, T., Siriopol, D. C., Kuwabara, M., İncir, S., Çamkıran, V., Rodríguez‐Iturbe, B., Lanaspa, M. A., et al. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13374 · Cited by 37
Plasma copeptin as a predictor of kidney disease
Enhörning, S., Christensson, A. G., & Melander, O. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy017 · Cited by 37
“As we previously found links between elevated copeptin and incident diabetes and hypertension [5, 7], we suspected that part of the association between elevated copeptin and CKD during follow-up would be driven by new-onset metabolic disease.”
BackgroundSelf-citationTaskin, M. I., Bulbul, E., Adali, E., Hismiogulları, A. A., & Inceboz, U. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.006 · Cited by 36
“There are recent studies that associate diabetes mellitus, cardiovascular risk, central obesity, and copeptin levels [12–14].”
BackgroundTap Water Consumption and Perceptions in United States Latinx Adults
Colburn, A. T., & Kavouras, S. A. (2021) · Nutrients · doi:10.3390/nu13092999 · Cited by 35
Jalleh, R. J., & Torpy, D. J. (2021) · Clinical Biochemist Reviews · doi:10.33176/aacb-20-00001 · Cited by 37
Karbek, B., Ozbek, M., Karakose, M., Topaloglu, O., Bozkurt, N., Cakır, E., Aslan, M., & Delibasi, T. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-31 · Cited by 35
“001) in a large population of 4742 subjects (cross-sectionally) [30].”
BackgroundMethodEricson, U., Rukh, G., Stojkovic, I., Sonestedt, E., Gullberg, B., Wirfält, E., Wallström, P., & Orho‐Melander, M. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.046474 · Cited by 35
“We used information on the date of diagnosis from the registries, which was prioritized in the following order: 1) the regional Diabetes 2000 Registry of Scania (33%) (17), 2) the Malmö Hemoglobin A1c Registry (49%) (18), and 3) the Swedish National Diabetes Registry (18%) (19).”
MethodSelf-citationProcalcitonin and Midregional Proatrial Natriuretic Peptide as Markers of Ischemic Stroke
Mira, K., Moon, Y. P., Paik, M. C., Müeller, B., Huber, A., Sacco, R. L., & Elkind, M. S. V. (2016) · Stroke · doi:10.1161/strokeaha.115.011392 · Cited by 34
“In a subcohort of the Malmö Diet and Cancer study, quartiles of copeptin had dose–response relationships with the odds of developing diabetes mellitus, even after additionally adjusting for baseline fasting glucose and insulin.(4) There is, however, less data available on the role of copeptin as prognostic marker for…”
Svensson, A. K., Svensson, T., Kitliński, M., Almgren, P., Engström, G., Nilsson, P. M., & Melander, O. (2017) · Diabetologia · doi:10.1007/s00125-017-4464-3 · Cited by 33
“The process of endpoint retrieval has been described in detail elsewhere [24].”
Self-citationFluid Intake and Vasopressin: Connecting the Dots
Guelinckx, I., Vecchio, M., Perrier, E. T., & Lemetais, G. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000446198 · Cited by 31
Then, C., Kowall, B., Lechner, A., Meisinger, C., Heier, M., Köenig, W., Peters, A., Rathmann, W., & Seißler, J. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0609-8 · Cited by 32
“This may be explained by the application of a novel-automated assay format as compared to the standard chemiluminescence test from the same manufacturer used in previous studies [5–9], but might also be due to different baseline characteristics of the study participants (as discussed below).”
BackgroundMethodResultInfluentialNoor, T., Hanif, F. M., Kiran, Z., Rehman, R., Khan, M. T., Haque, Z., & Nankani, K. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.05.018 · Cited by 32
Proneurotensin Predicts Cardiovascular Disease in an Elderly Population
Fawad, A., Bergmann, A., Struck, J., Nilsson, P. M., Orho‐Melander, M., & Melander, O. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02424 · Cited by 28
Self-citationCystatin C Is Not Causally Related to Coronary Artery Disease
Färbom, P., Almgren, P., Hedblad, B., Engström, G., Persson, M., Christensson, A. G., & Melander, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129269 · Cited by 31
“0 mmol/L), a self-reported physician diagnosis of diabetes, use of anti-diabetic medication or having been diagnosed in local or national Swedish diabetes registries, as described previously [32].”
Self-citationJárai, R., Mahla, E., Perkmann, T., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.06.024 · Cited by 31
Copeptin in fluid disorders and stress
Mu, D., Ma, C., Cheng, J. H., Zou, Y., Qiu, L., & Cheng, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.02.002 · Cited by 27
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 35
Zellweger, C., Wildi, K. S., Twerenbold, R., Reichlin, T., Naduvilekoot, A., Neuhaus, J. D., Balmelli, C., Gabutti, M., Afify, A. A., Ballarino, P., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.134 · Cited by 27
“Copeptin seems to have a special role in diabetic patients: recently published data [13,14] showed an increased risk for DM in patients with elevated copeptin levels.”
BackgroundResultBorné, Y., Nilsson, P. M., Melander, O., Hedblad, B., & Engström, G. (2015) · European Journal of Public Health · doi:10.1093/eurpub/ckv044 · Cited by 28
Self-citationAsferg, C. L., Andersen, U. B., Linneberg, A., Goetze, J. P., & Jeppesen, J. L. (2014) · Diabetic Medicine · doi:10.1111/dme.12411 · Cited by 26
Metadata
- Authors
- Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., Groop, L., Lyssenko, V., Orho-Melander, M., Newton-Cheh, C., & Melander, O.
- Affiliations
- From the Department of Clinical Sciences, Lund University (S.E., P.M.N., P.A., B.H., G.B., E.L., L.G., V.L., M.O.M., O.M.), and Department of Internal Medicine (S.E., P.M.N., O.M.), Malmö University Hospital, Malmö, Sweden; Cardiology Division (T.J.W., C.N.-C.), Center for Human Genetic Research (C.N.-C.), and Cardiovascular Research Center (T.J.W., C.N.-C.), Massachusetts General Hospital, Harvard Medical School, Boston; Program in Medical and Population Genetics, Broad Institute of Harvard and...
- Broad Institute (US)
- ORCID
- Venue
- Circulation
- Published
- 2010-05-18
- Volume
- 121
- Issue
- 19
- Pages
- 2102-2108
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC3763235
- OpenAlex
- W1963947490
- Cited by
- 299
- References
- 37
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 19 · 2023: 11 · 2022: 12 · 2021: 23 · 2020: 27 · 2019: 27 · 2018: 20 · 2017: 18 · 2016: 32 · 2015: 31 · 2014: 17 · 2013: 20 · 2012: 15
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL086875, R01HL083197, R01HL098283, K23HL080025)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081572)
- Topics
- Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- copeptin, diabetes mellitus, vasopressin, insulin resistance, incident diabetes risk, glucose metabolism, fasting insulin, fasting blood glucose, biomarkers of diabetes risk
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycopeptides, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Sweden, Prevalence, Multivariate Analysis, Logistic Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
